Treatment of cancer using organoarsenicals
AssigneeThe Florida International University Board of Trustees
InventorsBarry P. Rosen, Kunie Yoshinaga-Sakurai, Venkadesh Sarkarai Nadar
Life of this patent
Estimating the term…
Abstract
The subject invention provides organoarsenicals or salts thereof, compositions comprising an organoarsenical or a salt thereof, and methods of using the organoarsenicals or salts thereof, or compositions for inhibiting glutaminase and for treating cancers. Specifically, the subject invention provides methods of inhibiting glutaminase (e.g., KGA) catalytic activity in a cell, methods of treating cancer or a tumor via, for example, the inhibition of glutaminase activity, and methods of disrupting and/or inhibiting growth and proliferation of cancerous or tumorous cells.
Claims9
A method of inhibiting kidney-type glutaminase (KGA) activity in a cell that expresses KGA, comprising contacting the cell with a trivalent organoarsenical, or a salt thereof, wherein the trivalent organoarsenical is trivalent hydroxyarsinothricin or trivalent roxarsone.
A method of treating triple-negative breast cancer (TNBC), the method comprising administering to a subject having TNBC an effective amount of a composition comprising a trivalent organoarsenical, and a pharmaceutically-acceptable carrier, the trivalent organoarsenical being trivalent hydroxyarsinothricin or trivalent roxarsone.
A method of disrupting and/or inhibiting growth and proliferation of TNBC cells, the method comprising administering to a subject having TNBC an effective amount of a trivalent organoarsenical, the trivalent organoarsenical being trivalent hydroxyarsinothricin or trivalent roxarsone.
Dependencies are inferred from the claim text.